CASI Pharmaceuticals Stock Valuation

CASI
 Stock
  

USD 1.97  0.02  1.01%   

Do you want to know what the current value of CASI Pharmaceuticals is today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as CASI Pharmaceuticals, is its stock price multiplied by the total number of shares outstanding, calculating CASI Pharmaceuticals' enterprise value requires a different approach. It uses CASI Pharmaceuticals' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
CASI Pharmaceuticals Enterprise Value is most likely to increase significantly in the upcoming years. The preceding year's Enterprise Value was reported at 59.8 Million. The current Tangible Asset Value is estimated to increase to about 136 M, while Free Cash Flow is projected to decrease to (36.7 M).
CASI Pharmaceuticals shows a prevailing Real Value of $2.5 per share. The current price of the entity is $1.97. Based on Macroaxis valuation methodology, the entity appears to be undervalued. Our model approximates the value of CASI Pharmaceuticals from examining the entity fundamentals such as Shares Outstanding of 13.61 M, profit margin of (0.73) %, and Return On Asset of (0.15) % as well as evaluating its technical indicators and Probability Of Bankruptcy. In general, we favor locking in undervalued instruments and disposing overvalued instruments since, in the future, asset prices and their ongoing real values will blend.
  
CASI Pharmaceuticals Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as CASI Pharmaceuticals's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

CASI Pharmaceuticals Most Recent Valuation Data

Beta
0.42
change Receivables
-5.2 M
Fiscal Year End
December
property Plant And Equipment Net
21.8 M
Enterprise Value
-2.5 M
current Deferred Revenue
2.8 M
Undervalued
Today 1.97
Please note that CASI Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of CASI Pharmaceuticals is based on 3 months time horizon. Increasing CASI Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for CASI Pharmaceuticals is useful when determining the fair value of the CASI Pharmaceuticals stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of CASI Pharmaceuticals. Since CASI Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CASI Pharmaceuticals Stock. However, CASI Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
2.50
Real Value
7.07
Upside
Estimating the potential upside or downside of CASI Pharmaceuticals helps investors to forecast how CASI Pharmaceuticals stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CASI Pharmaceuticals more accurately as focusing exclusively on CASI Pharmaceuticals' fundamentals will not take into account other important factors:
Earnings
Estimates (2)
LowProjected EPSHigh
-0.34-0.31-0.28
Details
Hype
Prediction
LowEstimated ValueHigh
0.101.926.49
Details
Naive
Forecast
LowNext ValueHigh
0.0422242.116.68
Details
4 Analysts
Consensus
LowTarget PriceHigh
3.804.456.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use CASI Pharmaceuticals' intrinsic value based on its ongoing forecasts of CASI Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against CASI Pharmaceuticals' closest peers. When choosing an evaluation method for CASI Pharmaceuticals, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

CASI Pharmaceuticals Investments

41.41 Million

CASI Pharmaceuticals Valuation Drivers Correlation

Many accounts on the financial statements of CASI Pharmaceuticals are highly interrelated and sometimes correlated. Consequently, when conducting CASI Pharmaceuticals's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of CASI Pharmaceuticals
Click cells to compare fundamentals

CASI Pharmaceuticals Valuation Trend

Knowing CASI Pharmaceuticals' actual value is paramount for traders to make sound investment determinations. CASI Pharmaceuticals' real value is not only important for the investor to make better decisions but also for a more accurate overall view of CASI Pharmaceuticals' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both CASI Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

CASI Pharmaceuticals Market Cap

CASI Pharmaceuticals is number one stock in market capitalization category among related companies. Market capitalization of Health Care industry is currently estimated at about 119.04 Billion. CASI Pharmaceuticals adds roughly 27.08 Million in market capitalization claiming only tiny portion of equities under Health Care industry.
Capitalization  Revenue  Total debt  Valuation  Workforce

CASI Pharmaceuticals Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining CASI Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare CASI Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CASI Pharmaceuticals competition to find correlations between indicators driving CASI Pharmaceuticals's intrinsic value. More Info.
CASI Pharmaceuticals is number one stock in price to sales category among related companies. It is number one stock in beta category among related companies totaling about  0.57  of Beta per Price to Sales. The ratio of Price to Sales to Beta for CASI Pharmaceuticals is roughly  1.75 . Comparative valuation analysis is a catch-all model that can be used if you cannot value CASI Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for CASI Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CASI Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates CASI Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in CASI Pharmaceuticals and how it compares across the competition.

About CASI Pharmaceuticals Valuation

The stock valuation mechanism determines the current worth of CASI Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of CASI Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of CASI Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing CASI Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of CASI Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of CASI Pharmaceuticals. We calculate exposure to CASI Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to CASI Pharmaceuticals's related companies.
Fiscal Year End
December
Industry
Biotechnology
Concentration
Biotechnology
Full Time Employees
176.0
Service Category
Biotechnology
Employer Id Number
58-1959440
Last ReportedProjected for 2022
Gross Profit17.6 M19 M

CASI Pharmaceuticals Current Valuation Indicators

Valuation refers to the process of determining the present value of CASI Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value CASI Pharmaceuticals we look at many different elements of the entity such as CASI Pharmaceuticals's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. CASI Pharmaceuticals' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final CASI Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as CASI Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use CASI Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes CASI Pharmaceuticals' worth.
Continue to Trending Equities. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for analysis

When running CASI Pharmaceuticals price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Is CASI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
27.1 M
Quarterly Revenue Growth YOY
0.26
Return On Assets
(0.15) 
Return On Equity
(0.27) 
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine CASI Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.